Consolidated Statements of Stockholders Equity - USD ($)	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2017		$ 4,000	$ 192,670,000	$ (194,170,000)	$ (1,914,000)	$ (3,410,000)
Balance (in shares) at Dec. 31, 2017		3,671,014
Stock-based compensation	$ 0	$ 0	676,000	0	0	676,000
Fair Value of Warrants issued	0	0	9,000	0	0	9,000
Series A Preferred Stock Dividends	0	0	0	(59,000)	0	(59,000)
Net loss	$ 0	0	0	(2,316,000)	0	(2,316,000)
Non-controlling interest		0	0	0	(9,000)	(9,000)
Balance at Mar. 31, 2018		$ 4,000	193,355,000	(196,545,000)	(1,923,000)	(5,109,000)
Balance (in shares) at Mar. 31, 2018		3,671,014
Balance at Dec. 31, 2017		$ 4,000	192,670,000	(194,170,000)	(1,914,000)	(3,410,000)
Balance (in shares) at Dec. 31, 2017		3,671,014
Net loss						(10,194,000)
Non-controlling interest						(35,000)
Balance at Sep. 30, 2018		$ 5,000	200,807,000	(204,545,000)	(1,948,000)	(5,681,000)
Balance (in shares) at Sep. 30, 2018		5,349,002
Balance at Mar. 31, 2018		$ 4,000	193,355,000	(196,545,000)	(1,923,000)	(5,109,000)
Balance (in shares) at Mar. 31, 2018		3,671,014
Stock-based compensation			557,000			557,000
Series A Preferred Stock Dividends				(61,000)		(61,000)
Stock issued under "at-the-market" offering			400,000			400,000
Stock issued under "at-the-market" offering (in shares)	0	49,490
Net loss				(4,198,000)		(4,198,000)
Non-controlling interest					(16,000)	(16,000)
Balance at Jun. 30, 2018		$ 4,000	194,312,000	(200,804,000)	(1,939,000)	(8,427,000)
Balance (in shares) at Jun. 30, 2018		3,720,504
Stock-based compensation			475,000			475,000
Series A Preferred Stock Dividends				(61,000)		(61,000)
Stock issued under "at-the-market" offering		$ 1,000	6,020,000			6,021,000
Stock issued under "at-the-market" offering (in shares)		1,628,498
Net loss				(3,680,000)		(3,680,000)
Non-controlling interest					(9,000)	(9,000)
Balance at Sep. 30, 2018		$ 5,000	200,807,000	(204,545,000)	(1,948,000)	(5,681,000)
Balance (in shares) at Sep. 30, 2018		5,349,002
Balance at Dec. 31, 2018	$ 5,760,000	$ 15,000	230,754,000	(219,461,000)	(2,909,000)	14,159,000
Balance (in shares) at Dec. 31, 2018	9,161	15,482,083
Stock-based compensation	$ 0	$ 0	64,000	0	0	64,000
Series A Preferred Stock Dividends	0	0	0	(61,000)	0	(61,000)
Issuance of SYN Biomics Stock	0	0	(36,000)	0	53,000	17,000
Conversion of Series B Preferred Stock to Common	$ (638,000)	$ 1,000	1,035,000	(398,000)	0	0
Conversion of Series B Preferred Stock to Common (in shares)	(1,036)	900,869
Net loss	$ 0	$ 0	0	(3,512,000)	0	(3,512,000)
Non-controlling interest		0	0	0	(16,000)	(16,000)
Balance at Mar. 31, 2019	$ 5,122,000	$ 16,000	231,817,000	(223,432,000)	(2,872,000)	10,651,000
Balance (in shares) at Mar. 31, 2019	8,125	16,382,952
Balance at Dec. 31, 2018	$ 5,760,000	$ 15,000	230,754,000	(219,461,000)	(2,909,000)	14,159,000
Balance (in shares) at Dec. 31, 2018	9,161	15,482,083
Net loss						(12,163,000)
Non-controlling interest						(73,000)
Balance at Sep. 30, 2019	$ 4,822,000	$ 17,000	232,485,000	(232,394,000)	(2,841,000)	2,089,000
Balance (in shares) at Sep. 30, 2019	7,638	16,806,430
Balance at Mar. 31, 2019	$ 5,122,000	$ 16,000	231,817,000	(223,432,000)	(2,872,000)	10,651,000
Balance (in shares) at Mar. 31, 2019	8,125	16,382,952
Stock-based compensation	$ 0	$ 0	91,000	0	0	91,000
Series A Preferred Stock Dividends	0	0	0	(61,000)	0	(61,000)
Issuance of SYN Biomics Stock	0	0	0	0	45,000	45,000
Conversion of Series B Preferred Stock to Common	$ (187,000)	$ 1,000	303,000	(117,000)	0	0
Conversion of Series B Preferred Stock to Common (in shares)	(302)	262,608
Net loss		$ 0	0	(3,531,000)	0	(3,531,000)
Non-controlling interest		0	0	0	(27,000)	(27,000)
Balance at Jun. 30, 2019	$ 4,935,000	$ 17,000	232,211,000	(227,141,000)	(2,854,000)	7,168,000
Balance (in shares) at Jun. 30, 2019	7,823	16,645,560
Stock-based compensation	$ 0	$ 0	91,000	0	0	91,000
Series A Preferred Stock Dividends	0	0	0	(63,000)	0	(63,000)
Issuance of SYN Biomics Stock	0	0	0	0	43,000	43,000
Conversion of Series B Preferred Stock to Common	$ (113,000)	$ 0	183,000	(70,000)	0	0
Conversion of Series B Preferred Stock to Common (in shares)	(185)	160,870
Net loss	$ 0	$ 0	0	(5,120,000)	0	(5,120,000)
Non-controlling interest	0	0	0	0	(30,000)	(30,000)
Balance at Sep. 30, 2019	$ 4,822,000	$ 17,000	$ 232,485,000	$ (232,394,000)	$ (2,841,000)	$ 2,089,000
Balance (in shares) at Sep. 30, 2019	7,638	16,806,430